# Triple Negative Breast studies recruiting: 43 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials that are observational for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting observational Triple Negative Breast Neoplasms studies: 43 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/observational/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 43
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 19, 2026 | NCT07880600 | Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer | Fujian Cancer Hospital | Observational | Recruiting | Breast Neoplasm Female, Triple -Negative Breast Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880600) |
| October 9, 2026 | NCT07867470 | TROPION Breast Respond in 1L TNBC | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Observational | Not yet recruiting | Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867470) |
| October 2, 2026 | NCT07856225 | Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota | Observational | Recruiting | Breast Neoplasms, Triple Negative Breast Neoplasms, HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856225) |
| September 22, 2026 | NCT07833891 | Senocohort: Identification of Predictive Biomarkers in Breast Cancer Treatment | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Breast Cancer, Breast Cancer (Triple Negative Type) | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833891) |
| September 18, 2026 | NCT07828652 | Real-world Treatment Outcomes and Safety of Neoadjuvant Pembrolizumab-containing Therapy in Patients With Triple-negative Breast Cancer... | Sponsor not shown (see the record) | Observational | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828652) |
| September 8, 2026 | NCT07808086 | Role of Tumor Microbiota in the Response to Neoadjuvant Therapy in Patients Affected by Triple Negative Breast Cancer | Istituti Clinici Scientifici Maugeri SpA | Observational | Recruiting | Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808086) |
| July 15, 2026 | NCT07705438 | Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | Fudan University | Observational | Recruiting | Triple Negative Breast Cancer, Immune Checkpoint Inhibitor, Granzyme B PET/CT | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705438) |
| July 7, 2026 | NCT07687446 | Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer | Assistance Publique - Hôpitaux de Paris | Observational | Not yet recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687446) |
| June 23, 2026 | NCT07662252 | Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast Cancer | Federico II University | Observational | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2 + Breast Cancer | 186 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662252) |
| June 2, 2026 | NCT07619534 | Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior... | National Cancer Institute (NCI) | Observational | Recruiting | Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast | 139 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619534) |
| May 6, 2026 | NCT07570524 | Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer | Center Eugene Marquis | Observational | Recruiting | Triple-negative Breast Cancer (TNBC) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570524) |
| April 27, 2026 | NCT07551765 | Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and... | Barts & The London NHS Trust | Observational | Not yet recruiting | Triple Negative Breast Cancer (TNBC), Early Setting | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551765) |
| April 24, 2026 | NCT07551050 | Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer | Fudan University | Observational | Recruiting | TNBC - Triple-Negative Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551050) |
| April 23, 2026 | NCT07546695 | Role of Axillary Lymph Node Dissection for Residual MACROMETASTASES After NEOADJUVANT Chemotherapy in Patients With HER2+ and Triple... | University Hospital, Basel, Switzerland | Observational | Recruiting | Breast Cancer | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546695) |
| April 14, 2026 | NCT07527819 | Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC) | Peter MacCallum Cancer Centre, Australia | Observational | Not yet recruiting | Triple Negative Breast Cancer (TNBC) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527819) |
| April 13, 2026 | NCT07523789 | Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC | The First Affiliated Hospital with Nanjing Medical University | Observational | Not yet recruiting | TNBC, Triple Negative Breast Cancer | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523789) |
| January 12, 2026 | NCT07332975 | ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC | University of Pittsburgh | Observational | Recruiting | Triple Negative Breast Cancer | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332975) |
| January 8, 2026 | NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) | Elephas | Observational | Recruiting | Cancer, Immunotherapy, Advanced Solid Tumors Cancer, Bladder Cancer, TNBC, Triple Negative Breast Cancer, Colorectal... | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07327489) |
| December 3, 2025 | NCT07260188 | Organoids From Breast Cancer Patients Treated With Neoadjuvant Therapy | Istituti Clinici Scientifici Maugeri SpA | Observational | Recruiting | Invasive Breast Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260188) |
| November 24, 2025 | NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis | OncoHost Ltd. | Observational | Not yet recruiting | Non Small Cell Lung Cancer (NSCLC), Melanoma (Skin Cancer), Triple Negative Breast Cancer (TNBC), RCC, Renal Cell... | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246759) |
| October 7, 2025 | NCT07211178 | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | Tempus AI | Observational | Recruiting | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer... | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07211178) |
| July 24, 2025 | NCT07084571 | Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution | Royal Marsden NHS Foundation Trust | Observational | Recruiting | Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07084571) |
| July 18, 2025 | NCT07073755 | Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd | Hunan Cancer Hospital | Observational | Recruiting | Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer, HER2-positive Breast Cancer... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07073755) |
| May 28, 2025 | NCT06991790 | Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration | Peking University Cancer Hospital & Institute | Observational | Recruiting | TNBC | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06991790) |
| January 29, 2025 | NCT06798506 | Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer | Fudan University | Observational | Not yet recruiting | TNBC - Triple-Negative Breast Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06798506) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| Royal Marsden NHS Foundation Trust | 2 |
| Istituti Clinici Scientifici Maugeri SpA | 2 |
| Peking University People's Hospital | 1 |
| Fundación Santa Fe de Bogota | 1 |
| Hunan Cancer Hospital | 1 |
| OncoHost Ltd. | 1 |
| Emory University | 1 |
| Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 1 |
| Federico II University | 1 |
| Tempus AI | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| National Cancer Institute (NCI) | 1 |
| University of California, San Francisco | 1 |
| VastBiome | 1 |
| Elephas | 1 |
| University Hospital, Basel, Switzerland | 1 |
| University College Cork | 1 |
| Centre Francois Baclesse | 1 |
| Cofactor Genomics, Inc. | 1 |
| Vall d'Hebron Institute of Oncology | 1 |
| Center Eugene Marquis | 1 |
| University of Pittsburgh | 1 |
| Barts & The London NHS Trust | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| China | 10 |
| Italy | 3 |
| United Kingdom | 3 |
| Germany | 2 |
| Spain | 2 |
| France | 2 |
| Colombia | 1 |
| Switzerland | 1 |
| Ireland | 1 |
| Indonesia | 1 |
| Vietnam | 1 |
| Netherlands | 1 |
| Australia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Water heater installers in the United States](https://specstream.ai/data/businesses/water-heater-installers/united-states)
- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [HVAC contractors in the United States](https://specstream.ai/data/businesses/hvac-contractors/united-states)
- [Electricians in the United States](https://specstream.ai/data/businesses/electricians/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
